Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Q4 2018 Karyopharm Therapeutics Inc Earnings Call Transcript

Feb 28, 2019 / 01:30PM GMT
Release Date Price: €3.7 (-6.33%)
Operator

Good morning. My name is Liz, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Fourth Quarter and Full Year 2018 Financial Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Mr. Ian Karp, Karyopharm's Vice President, Investor and Public Relations.

Ian Karp
Karyopharm Therapeutics Inc. - VP of Investor & Public Relations

Thank you, Liz, and thank you all for joining us on today's conference call to discuss Karyopharm's fourth quarter and full year 2018 financial results and business update. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, Chief Executive Officer; Mike Mason, Chief Financial Officer; Dr. Sharon Shacham our Founder, President and Chief Scientific Officer; Christopher Primiano, Chief Business Officer and General Counsel; Anand Varadan, our Chief Commercial Officer; Dr. Jatin Shah, Senior Vice President, Clinical Development; and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot